Cost a focus as GSK takes lead in new wave of biotech lung drugs

September 8, 2014 2:10 PM

3 0

Cost a focus as GSK takes lead in new wave of biotech lung drugs

Ganesh Chaturthi Festival

LONDON (Reuters) - Cost-effectiveness is seen as a challenge for a new group of biotech lung drugs that have produced promising results in clinical tests, of which the first is likely to be launched next year by GlaxoSmithKline.

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...